CTLA4 and hepatocellular carcinoma: Currently, BsAbs developed for HCC including PD1/CTLA4 (e.g. AK104), PD-L1/CTLA4 (e.g. KN046), PD-L1/LAG3(e.g. Tebotelimab) and GPC3/CD3 [4].